NFE2L2 and diabetic kidney disease: Fewer patients from the bardoxolone methyl group than the placebo group progressed to ESRD and the improvement in the eGFR noticed in the BEAM trial was present also in the BEACON study, keeping hope alive in the treatment of DKD via targeting the NRF2/KEAP1 pathway and emphasizing the need for a different perspective [73].